Daurismo
Daurismo ingredients
| Active ingredient | Strength |
|---|---|
| Glasdegib | 100 mg/1, 25 mg/1 |
What Daurismo is used for
The FDA lists the approved uses on the official label (below). In the EU, glasdegib is approved as Daurismo for:
Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Daurismo
- Generic name
- Glasdegib
- Made by
- Pfizer Laboratories Div Pfizer Inc
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Hedgehog Pathway Inhibitor
- FDA approval
- New drug application (NDA) NDA210656
- On the US market since
- 2018
Official information
- Daurismo prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Glasdegib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Daurismo?
Daurismo (Glasdegib) is a cancer medicine made by Pfizer Laboratories Div Pfizer Inc, approved by the US FDA.
What are the ingredients of Daurismo?
Daurismo contains Glasdegib (100 mg/1, 25 mg/1).
Is Daurismo approved in Europe?
The same active substance is approved in the EU as Daurismo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA